Aquestive Therapeutics Inc (NASDAQ:AQST) reported its financial results for the fourth quarter and full year of 2025, delivering a mixed performance against analyst expectations while providing a crucial update on the regulatory path for its lead product candidate, Anaphylm. The market's initial reaction, reflected in after-hours trading, was negative.
Earnings Versus Estimates
The company's top-line revenue for the fourth quarter came in slightly below consensus, while its bottom-line loss was wider than anticipated.
- Q4 2025 Revenue: Reported at $13.0 million, compared to the analyst estimate of $13.5 million.
- Q4 2025 EPS: Reported a net loss per share of ($0.26), which was significantly wider than the estimated loss of ($0.14).
The wider-than-expected loss was primarily driven by a substantial increase in selling, general, and administrative (SG&A) expenses, which rose to $32.8 million in the quarter from $16.0 million in the prior year period. This surge was largely attributed to approximately $13.6 million in one-time legal expenses related to a settlement and increased commercial spending in preparation for the potential launch of Anaphylm.
Market Reaction and Financial Health
Following the earnings release, AQST shares traded lower in the after-market session. This immediate reaction suggests investor focus on the earnings miss and the continued cash burn as the company funds its development pipeline. For the full year 2025, Aquestive's net loss expanded to $83.8 million from $44.1 million in 2024.
However, the company's balance sheet shows a strengthened cash position. As of December 31, 2025, cash and cash equivalents stood at $121.2 million, a significant increase from $71.5 million at the end of 2024. This provides a financial runway as the company navigates its key upcoming milestones.
Key Business Updates from the Report
The earnings release was heavily focused on the regulatory status and future plans for Anaphylm, a sublingual film epinephrine product designed for severe allergic reactions.
- Anaphylm Regulatory Path: The company reaffirmed its plan to resubmit the New Drug Application (NDA) in the third quarter of 2026. This follows a Complete Response Letter (CRL) from the FDA in January 2026, which cited deficiencies related to human factors validation studies (specifically pouch opening and film placement) and requested one additional pharmacokinetics study. The FDA did not question the clinical efficacy or safety data, and no chemistry or manufacturing issues were identified.
- Extended Partnership: Aquestive announced an amendment to its agreement with RTW Investments, extending the marketing approval deadline for Anaphylm to June 30, 2027. Concurrently, RTW-affiliated funds committed to purchasing at least $5 million of AQST common stock over the next 90 days.
- Pipeline Progress: The company is advancing AQST-108, a topical epinephrine gel for potential dermatological conditions like alopecia areata. A Phase 1 data readout is expected in the second quarter of 2026.
- 2026 Financial Guidance: Management provided its outlook for the full year, which appears conservative relative to existing analyst sales forecasts.
- Aquestive's 2026 Revenue Guidance: $46 to $50 million.
- Analyst 2026 Sales Estimate: $50.9 million.
- The company also expects its non-GAAP adjusted EBITDA loss to be between $35 million and $30 million.
Conclusion
Aquestive Therapeutics' fourth-quarter earnings presented a familiar narrative for clinical-stage biopharma companies: increased near-term financial losses funding a critical regulatory push. While the revenue miss and widened loss contributed to negative after-hours sentiment, the primary investment thesis for AQST remains squarely focused on the successful resubmission and ultimate approval of Anaphylm. The company's updated cash position and reaffirmed regulatory timeline offer a clearer, albeit delayed, path forward. Investors will now watch closely for the upcoming Type A meeting with the FDA and progress on the required studies.
For a detailed history of earnings and analyst estimates, visit the AQST earnings page on Chartmill.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an endorsement, or a recommendation to buy, sell, or hold any security. Investing involves risk, including the potential loss of principal.
